Manufacturing News and Research

RSS

Manufacturing is the production of products across all industries, on a large-scale, using machinery.

GTC Biotherapeutics reports total net loss of $1.7M for fourth-quarter 2009

GTC Biotherapeutics, Inc. today reported its financial results for the fourth quarter and fiscal year ended January 3, 2010. The total net loss for the fourth quarter was $1.7 million, or $0.09 per share, compared with $6.2 million, or $0.60 per share, for the fourth quarter of 2008. The total net loss for 2009 was $27.9 million, or $2.18 per share, compared to $22.7 million, or $2.31 per share, for 2008.

12 Mar 2010

Halozyme Therapeutics reports net loss of $12.7M for fourth-quarter of 2009

Halozyme Therapeutics, Inc., a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the endocrinology, oncology, dermatology and drug delivery markets, today reported financial results for the fourth quarter and year ended December 31, 2009.

12 Mar 2010

Arena Pharmaceuticals reports lower net loss allocable to common stockholders in fourth-quarter 2009

Arena Pharmaceuticals, Inc. today reported financial results for the fourth quarter and full year ended December 31, 2009.

12 Mar 2010

Neoprobe meets with FDA to review Phase 3 clinical trial results of Lymphoseek drug

Neoprobe Corporation, a diversified developer of innovative oncology and surgical diagnostic and treatment products, today announced that it recently met with the United States Food and Drug Administration to review the clinical trial results of a Phase 3 investigational new drug, Lymphoseek®.

12 Mar 2010

Roche Diagnostics purchases NimbleGen microarray workflow assets from BioMicro Systems

Roche Diagnostics has purchased assets from BioMicro Systems for all products associated with the Roche NimbleGen microarray workflow. These assets consist of key instrumentation in the comprehensive Roche NimbleGen microarray workflow including the NimbleGen Hybridization Systems (both 4- and 12-bay models).

12 Mar 2010

Baxter International, DVC present Phase III clinical efficacy data for PREFLUCEL

Baxter International Inc., in conjunction with DynPort Vaccine Company LLC, a CSC Company, today presented Phase III study data measuring the clinical efficacy for PREFLUCEL, a trivalent seasonal influenza candidate vaccine. PREFLUCEL is made using Baxter’s Vero cell culture platform and does not contain an adjuvant or preservatives. The data were presented at the International Congress on Infectious Disease (ICID) in Miami, Florida.

From Baxter International Inc. 12 Mar 2010

Covidien to use FDA, Health Canada approved Mo 99 from Maria for manufacturing Tc 99m generators

Covidien, a leading global provider of healthcare products, today announced that the U.S. Food and Drug Administration (FDA) and Health Canada have approved the use of the Maria Research Reactor (Maria) in Poland as a site to irradiate highly-enriched uranium targets for Molybdenum 99 (Mo 99) production. Covidien will use the Mo 99 obtained from Maria in the manufacture of its Technetium 99m (Tc 99m) generators. Patients should begin to benefit from Maria-produced Mo 99 in the United States and Canada later this month.

12 Mar 2010

Peregrine Pharmaceuticals' third-quarter fiscal 2010 total revenues up 45%

Peregrine Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing innovative monoclonal antibodies for the treatment of cancer and serious viral infections, today announced financial results for the third quarter of fiscal year (FY) 2010 ended January 31, 2010. The company also provided an update on its clinical programs and corporate developments.

From Thermo Fisher Scientific Inc. 11 Mar 2010

Lorom West certifies to ISO 13485: 2003 QMS for Medical Devices

Lorom West, a premier manufacturer of custom cables, wire harnesses, PCB and high quality OEM/ODM products today announced successful certification to the ISO 13485: 2003 Quality Management Standard (QMS) for Medical Devices.

11 Mar 2010

Safeguard Scientifics' aggregate partner company revenue rises 46% in 2009

Safeguard Scientifics, Inc., a holding company that builds value in growth-stage life sciences and technology companies, today announced that aggregate revenue of its partner companies for the year was $262 million, up 46% from $179 million in 2008, exceeding the company’s 2009 guidance of $223 million to $243 million, as adjusted to reflect the inclusion of two new partner companies.

11 Mar 2010

Columbia Laboratories' fourth-quarter 2009 net revenues up 21%

Columbia Laboratories, Inc. today reported financial results of the three- and twelve-months periods ended December 31, 2009.

11 Mar 2010

BioInvent International, HGS announce collaboration to develop therapeutic monoclonal antibodies

BioInvent International AB and Human Genome Sciences, Inc. today announced that they have entered into a collaboration to discover, develop and commercialize therapeutic monoclonal antibodies which specifically target antigens discovered by HGS.

11 Mar 2010

HGS, BioInvent International AB to discover, develop and commercialize therapeutic monoclonal antibodies

Human Genome Sciences, Inc. and BioInvent International AB today announced that they have entered into a collaboration to discover, develop and commercialize therapeutic monoclonal antibodies that specifically target antigens discovered by HGS.

11 Mar 2010

Quantum Polymers offers AvaSpire modified PEEK resin based plastic products

Quantum Polymers today announced the availability of extruded stock shape plastic products made with AvaSpire® resin from Solvay Advanced Polymers (Alpharetta, Ga.). AvaSpire is a modified polyetheretherketone (PEEK) resin that has been formulated to offer improved ductility, mechanical strength and higher operating temperature relative to PEEK while retaining most of the key performance attributes of PEEK at a lower price point.

11 Mar 2010

Molecular master switch plays a key role in maturation process of brain cells

About four out of every 10 cells in the brain are so-called oligodendrocytes. These cells produce the all-important myelin that coats nerve tracts, ensuring fast, energy-efficient transmission of nerve impulses.

11 Mar 2010

Veterans PTSD Project: Cannabis Science formalizes agreement with specialized FDA regulatory compliance firm

Cannabis Science, Inc., a pioneering pharmaceutical cannabis company, is pleased to announce that it has formalized its agreement with a privately owned, highly specialized international FDA regulatory compliance firm. The compliance firm will review and prepare technical data for Cannabis Science's FDA Pre-Investigative New Drug submission package for its Veterans PTSD Project.

11 Mar 2010

PBI and TDI announce strategic licensing and collaborative research and development agreement

Pressure BioSciences, Inc. and Target Discovery, Inc.,, today announced a strategic product licensing, manufacturing, co-marketing, and collaborative research and development agreement. Under the terms of the Agreement, PBI has been licensed by TDI to manufacture and sell a highly innovative line of chemicals used in the preparation of tissues for scientific analysis.

11 Mar 2010

Chelsea Therapeutics announces financial results for fourth quarter 2009

Chelsea Therapeutics International, Ltd. reported financial results for the fourth quarter and full year 2009 and will host a conference call this afternoon at 4:30 PM ET to discuss these results and provide a quarterly update on the Company's development progress.

11 Mar 2010

Discovery Laboratories reports net loss of $6.1M for fourth-quarter 2009

Discovery Laboratories, Inc. today announces financial results for the fourth quarter ended December 31, 2009 and provides a business update.

10 Mar 2010

Bavarian Nordic' Annual Report 2009

Today Bavarian Nordic published the company's Annual Report 2009. The report is available on the company's website: www.bavarian-nordic.com

10 Mar 2010

Manufacturing News and Research

Further Reading

GTC Biotherapeutics reports total net loss of $1.7M for fourth-quarter 2009

Halozyme Therapeutics reports net loss of $12.7M for fourth-quarter of 2009

Arena Pharmaceuticals reports lower net loss allocable to common stockholders in fourth-quarter 2009

Neoprobe meets with FDA to review Phase 3 clinical trial results of Lymphoseek drug

Roche Diagnostics purchases NimbleGen microarray workflow assets from BioMicro Systems

Baxter International, DVC present Phase III clinical efficacy data for PREFLUCEL

Covidien to use FDA, Health Canada approved Mo 99 from Maria for manufacturing Tc 99m generators

Peregrine Pharmaceuticals' third-quarter fiscal 2010 total revenues up 45%

Lorom West certifies to ISO 13485: 2003 QMS for Medical Devices

Safeguard Scientifics' aggregate partner company revenue rises 46% in 2009

Columbia Laboratories' fourth-quarter 2009 net revenues up 21%

BioInvent International, HGS announce collaboration to develop therapeutic monoclonal antibodies

HGS, BioInvent International AB to discover, develop and commercialize therapeutic monoclonal antibodies

Quantum Polymers offers AvaSpire modified PEEK resin based plastic products

Molecular master switch plays a key role in maturation process of brain cells

Veterans PTSD Project: Cannabis Science formalizes agreement with specialized FDA regulatory compliance firm

PBI and TDI announce strategic licensing and collaborative research and development agreement

Chelsea Therapeutics announces financial results for fourth quarter 2009

Discovery Laboratories reports net loss of $6.1M for fourth-quarter 2009

Bavarian Nordic' Annual Report 2009

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest Life Science News